Compare Ascendis Pharma A/S (ASND) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Quantum Computing Inc — how do they compare? Ascendis Pharma A/S trades at $265.33 (market cap $17.74B), while Quantum Computing Inc trades at $7.98 (market cap $1.95B). The key difference: Ascendis Pharma A/S is far larger — about 9.1× Quantum Computing Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| ASND | QUBT | |
|---|---|---|
Market Cap | $17.74B | $1.95B |
Sector | Health | Technology |
52-Week High | $277.18 | $24.62 |
52-Week Low | $163.32 | $6.31 |
Enterprise Value | $18.11B | $970.72M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Quantum Computing Inc. (QUBT) trades at $8.66, down 5.36% today, with a bearish technical outlook but strong analyst support. The company reported a net loss of $18.67 million on minimal revenue of $682,000 in 2025, reflecting high cash burn. Recent strategic acquisitions and a $10 million framework agreement with Planck Dynamics highlight growth initiatives, yet profitability remains distant amid negative margins.
QUBT offers speculative upside with a consensus price target of $24.00 (177% potential), but faces significant execution and funding risks. Investors must weigh long-term quantum technology potential against persistent losses and the need for substantial capital to survive until commercialization, making it suitable only for high-risk portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
